Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Durect Reports Positive Phase IIb Results For Posidur In Post-Op Hernia Pain

This article was originally published in The Pink Sheet Daily

Executive Summary

Posidur, co-developed with Nycomed, has the potential to become a more than $2 billion opportunity, Durect CFO tells “The Pink Sheet” DAILY.
Advertisement

Related Content

Remoxy NDA Set For Q2 Following Positive Phase III Results
Remoxy NDA Set For Q2 Following Positive Phase III Results
Durect and Nycomed To Collaborate On Anesthetic Posidur In $202 Mil. Deal
Durect and Nycomed To Collaborate On Anesthetic Posidur In $202 Mil. Deal
King Signs On To Develop Pain Therapeutics’ Abuse-Resistant Oxycodone

Topics

Advertisement
UsernamePublicRestriction

Register

PS066321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel